Notices

Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) listed as known to cause cancer under Proposition 65.

Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011

Extension of public comment period regarding the removal of the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested. 

Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) was listed effective 10/28/2011 as known to the State to cause cancer.

Extension of comment period regarding the establishment of a specific regulatory level posing no significant risk for Imazalil.

Notice of adoption to text of regulations Title 27, California Code of Regulations amendment to section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1

Extension of public comment period on the changed notice of proposed rulemaking establishing a  No Significant Risk Level: 4-Methylimidazole (4-MEI).

Announcement of the October 12th and 13th2011 CIC meeting and hazard ID materials for fluoride and its salts, and tris(1,3-Dichloro-2-Propyl) phosphate.  Both will be considered for listing at the October 2011 meeting.

Comment period for the Changed Notice of Proposed Rulemaking Specific Regulatory Levels Posing No Significant Risk: 4-Methylimidazole (4-MEI).

The proposed NSRL for 4-MEI has been changed from 16 to to 29 micrograms per day.

Proposal to add a NSRL for imazalil of 11ug/day.

A notice to establish a specific regulatory level posing no significant risk for imazalil was posted on the OEHHA website and published in the CRNR on September 9, 2011. OEHHA is withdrawing that notice because a number of non-substantive, clarifying changes to the notice were required.

Notice to propose establishment of a specific regulatory level posing no significant risk for imazalil and amend Title 27, California Code of Regulations, section 25705.

Proposal to amend Section 25707, which would remove the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested, based on recent scientific findings that establish that chromium (hexavalent compounds) can be carcinogenic by the oral route.

Intent to list chemicals by the labor code mechanism: Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture).

This amendment would remove the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested, based on recent scientific findings that establish that chromium (hexavalent compounds) can be carcinogenic by the oral route.

Proposal to establish a NSRL of 11 ug/day for Imazalil

This action would amend existing procedures governing service of a 60-day notice under Proposition 65 by establishing an alternative procedure for serving notices on the Attorney General via electronic mail.

OEHHA is adding titanium dioxide (airborne, unbound particles of respirable size) to the list of chemicals known to the state of California to cause cancer for purposes of the Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65).

On June 24, 2011, the California Environmental Protection Agency’s (Cal/EPA) Office of Environmental Health Hazard Assessment (OEHHA) published a notice extending the public comment period soliciti